Our results demonstrated the potential for implementation of proteomic screening, in a preventative manner even years before the onset of overt MM, to identify the subgroup of individuals at highest risk, and highlight the possibility to test whether they represent those who would eventually benefit the most from assessment of anti-TNFRSF17 as earlier lines of treatment. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.